

Dose Comparisons of Clopidogrel and Aspirin in Acute C

New England Journal of Medicine

363, 930-942

DOI: [10.1056/nejmoa0909475](https://doi.org/10.1056/nejmoa0909475)

Citation Report

#	ARTICLE	IF	CITATIONS
1	HERBERT DINGLE [1972]: Science at the Crossroads. London: Martin Brian and O'Keeffe. Pp. 256. Â£3.00. British Journal for the Philosophy of Science, 1975, 26, 358-362.	1.4	2
2	Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. Revista Espanola De Cardiologia Suplementos, 2010, 10, 42-48.	0.2	0
3	Oral Antiplatelet Therapy in Patients with Diabetes Mellitus and Acute Coronary Syndromes. Trends in Cardiovascular Medicine, 2010, 20, 211-217.	2.3	3
6	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation, 2010, 122, 2619-2633.	1.6	281
7	Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?. Heart, 2010, 96, 1693-1694.	1.2	41
8	<i>Circulation</i> Cardiovascular Case Series. Circulation, 2010, 122, 1661-1661.	1.6	0
9	Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease. Clinical Medicine Insights: Cardiology, 2010, 4, CMC.S4323.	0.6	20
10	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology, 2010, 105, 2533-2549.	0.2	153
12	Fine-Tuning Therapy for Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 976-977.	13.9	6
13	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2010, 45, 953-955.	0.4	0
14	Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor. Cardiology, 2010, 117, 231-233.	0.6	14
15	Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European Heart Journal, 2010, 31, 2971-2973.	1.0	7
16	Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 2465-2468.	13.9	2
18	ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2010, 56, 2051-2066.	1.2	203
19	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2010, 56, 2126-2138.	1.2	31
20	Geriatric Pharmacotherapy Updates. American Journal of Geriatric Pharmacotherapy, 2010, 8, 599-609.	3.0	1
21	The effects of laropiprant, a selective prostaglandin D2receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets, 2011, 22, 495-503.	1.1	9
22	Syndrome coronarien: risques ischémiques et risques hémorragiques. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, 28-30.	0.0	1

#	ARTICLE	IF	CITATIONS
23	Antiplatelet Therapy in Coronary Heart Disease Prevention. <i>Cardiology Clinics</i> , 2011, 29, 71-85.	0.9	10
24	Syndrome coronaire aigu sans sus-décalage du segment ST: prise en charge thérapeutique. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2011, 2011, 15-21.	0.0	0
25	High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelial Function, and Inflammation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 771-778.	1.2	77
26	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Journal of the American College of Cardiology</i> , 2011, 57, 1920-1959.	1.2	332
27	On-Clopidogrel Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1955-1957.	1.2	0
28	The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2342-2354.	1.2	7
29	Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1285-1295.	0.9	42
30	Genetic variability in response to clopidogrel therapy and its clinical implications. <i>Thrombosis and Haemostasis</i> , 2011, 105, S55-S59.	1.8	22
31	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	1.8	188
32	Triple Antiplatelet Therapy in Acute Coronary Syndromes. <i>Drugs</i> , 2011, 71, 1703-1719.	4.9	13
33	Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. <i>BMC Medicine</i> , 2011, 9, 3.	2.3	79
34	The evolution of antiplatelet therapy in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 547-559.	6.1	84
35	Pharmacogenomic Testing in Current Clinical Practice. , 2011, , .		2
36	Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. <i>American Heart Journal</i> , 2011, 161, 450-461.	1.2	30
37	Design and rationale of the Radial Vs. femoral access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2011, 161, 254-260.e4.	1.2	46
38	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	0.8	106
39	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment - Part 1: Non-ST-Segment Elevation ACS. <i>Canadian Journal of Cardiology</i> , 2011, 27, S387-S401.	0.8	29
40	High on Treatment Platelet Reactivity and Stent Thrombosis. <i>Heart Lung and Circulation</i> , 2011, 20, 525-531.	0.2	12

#	ARTICLE	IF	CITATIONS
41	Current concepts on coronary revascularization in diabetic patients. <i>European Heart Journal</i> , 2011, 32, 2748-2757.	1.0	82
42	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2999-3054.	1.0	2,995
44	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. <i>Future Cardiology</i> , 2011, 7, 381-402.	0.5	13
46	Double-dose clopidogrel in patients undergoing PCI for ACS. <i>Lancet, The</i> , 2011, 377, 297.	6.3	1
47	Double-dose clopidogrel in patients undergoing PCI for ACS. <i>Lancet, The</i> , 2011, 377, 297.	6.3	0
48	Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply. <i>Lancet, The</i> , 2011, 377, 298.	6.3	1
49	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. <i>Lancet, The</i> , 2011, 377, 1409-1420.	6.3	1,759
50	Clopidogrel withdrawal: Is there a ‘rebound’ phenomenon?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 211-220.	1.8	55
51	Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. <i>Thrombosis and Haemostasis</i> , 2011, 105, S67-S74.	1.8	28
52	The genetic basis of platelet responsiveness to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2011, 106, 203-210.	1.8	13
53	Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists. <i>Current Drug Targets</i> , 2011, 12, 1805-1812.	1.0	4
54	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>Yearbook of Critical Care Medicine</i> , 2011, 2011, 57-60.	0.2	0
55	Role of Platelets and Antiplatelet Therapy in Cardiovascular Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 431-442.	0.9	46
56	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 658-671.	1.1	34
57	Antiplatelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual antiplatelet therapy. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 619-633.	1.1	172
58	Managing acute coronary syndromes in the prehospital and emergency setting: New guidelines from the Australian Resuscitation Council and New Zealand Resuscitation Council. <i>EMA - Emergency Medicine Australasia</i> , 2011, 23, 240-243.	0.5	0
59	Low-Dose versus High-Dose Aspirin after Percutaneous Coronary Intervention: Analysis from the Guthrie Health Off-Label StenT (GHOST) Registry. <i>Journal of Interventional Cardiology</i> , 2011, 24, 307-314.	0.5	9
60	The Role of Antiplatelets in Hypertension and Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2011, 13, 305-313.	1.0	9

#	ARTICLE	IF	CITATIONS
61	Atherothrombosis and the role of antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 325-332.	1.9	21
62	L'offre antiplaquettaire s'améliore. <i>Option/Bio</i> , 2011, 22, 14-15.	0.0	0
63	Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. <i>Current Problems in Cardiology</i> , 2011, 36, 375-401.	1.1	11
64	Safety and Efficacy of Clopidogrel Reloading in Patients on Chronic Clopidogrel Therapy Who Present With an Acute Coronary Syndrome and Undergo Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2011, 107, 1779-1782.	0.7	8
65	Best Clinical Trials Reported in 2010. <i>American Journal of Cardiology</i> , 2011, 108, 162-168.	0.7	0
66	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 760-765.	0.7	40
67	Comparison of Platelet Reactivity and Clopidogrel Response in Patients >75 Years Versus <75 Years Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1411-1416.	0.7	18
68	Clopidogrel in acute coronary syndromes: Where are we now?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 766-773.	1.8	6
69	No free lunches: balancing bleeding and efficacy with ticagrelor. <i>European Heart Journal</i> , 2011, 32, 2919-2921.	1.0	3
70	Influence of Low-Dose Aspirin (81 mg) on the Incidence of Definite Stent Thrombosis in Patients Receiving Bare-Metal and Drug-Eluting Stents. <i>Clinical Cardiology</i> , 2011, 34, 567-571.	0.7	3
71	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	1.0	203
73	Present and future of secondary prevention after an acute coronary syndrome. <i>EPMA Journal</i> , 2011, 2, 371-379.	3.3	6
74	Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. <i>Current Cardiology Reports</i> , 2011, 13, 303-311.	1.3	1
75	Triple therapy in hospitalized patients: Facts and controversies. <i>Journal of Hospital Medicine</i> , 2011, 6, 537-545.	0.7	1
76	Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 381-391.	1.1	46
77	The optimal pharmacological formula for percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1075-1086.	0.9	0
78	Antiplatelet options for secondary prevention in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1403-1415.	0.6	1
79	Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 1315-1328.	0.0	0

#	ARTICLE	IF	CITATIONS
80	Evaluating the Risk-Benefit Profile of the Direct-Acting P2Y ₁₂ Inhibitor Ticagrelor in Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2011, 123, 79-90.	0.9	6
81	Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. <i>Biomarkers in Medicine</i> , 2011, 5, 9-30.	0.6	3
82	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 2362-2364.	13.9	7
83	Rivaroxaban in the contemporary treatment of acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 849-857.	1.9	4
84	Prescribing proton pump inhibitor and clopidogrel together. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 558-564.	1.0	14
85	Updating the Chest Pain Algorithm. <i>Critical Pathways in Cardiology</i> , 2011, 10, 9-16.	0.2	6
86	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 561-569.	0.2	34
87	Recent developments in the use of antiplatelet agents to prevent cardiovascular events. <i>Future Cardiology</i> , 2011, 7, 403-413.	0.5	6
88	Thienopyridines in Acute Coronary Syndrome. <i>Annals of Pharmacotherapy</i> , 2011, 45, 207-217.	0.9	2
89	Defining the optimal dose of aspirin and clopidogrel in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 149-151.	0.9	1
90	Variability of clopidogrel response in patients with type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 245-253.	0.9	28
91	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1097.	3.8	1,185
92	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-“ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). <i>Circulation</i> , 2011, 123, 2022-2060.	1.6	321
93	Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 180-187.	1.4	172
94	Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Intervention—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2520.	3.8	1
95	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	3.8	179
96	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	1.4	103
98	What Should We Be Fine Tuning in Acute Coronary Syndromes—Dosing of Antiplatelet Therapy or Data Presentation?. <i>Annals of Pharmacotherapy</i> , 2011, 45, 120-122.	0.9	0

#	ARTICLE	IF	CITATIONS
99	Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2011, 32, 2989-2997.	1.0	71
100	Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 95-103.	1.4	13
101	Platelet-Mediated Thrombosis and Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 629-637.	1.4	7
102	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	1.0	41
103	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
104	P2Y Receptors in Health and Disease. <i>Advances in Pharmacology</i> , 2011, 61, 417-439.	1.2	26
105	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation</i> , 2011, 124, 544-554.	1.6	397
106	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
107	What is the best dose of aspirin in association with P2Y12 antagonists?. <i>Heart</i> , 2011, 97, 263-264.	1.2	5
108	Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. <i>Heart</i> , 2011, 97, 887-891.	1.2	20
109	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	1.4	19
110	Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome. <i>Circulation</i> , 2011, 123, 798-813.	1.6	272
111	The safety of clopidogrel. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 85-95.	1.0	13
112	Thrombin Generation in Hemorrhage Control and Vascular Occlusion. <i>Circulation</i> , 2011, 124, 225-235.	1.6	67
113	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq0 100 rgBT /Overlock 1		
114	Current antiplatelet options for NSTEMI-ACS patients. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 935-948.	0.2	5
115	Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-18.	0.5	26
116	Prostanoids, Aspirin, and Related Compounds. , 2012, , 168-171.		0

#	ARTICLE	IF	CITATIONS
117	A brief review of the past and future of platelet P2Y ₁₂ antagonist. <i>Coronary Artery Disease</i> , 2012, 23, 368-374.	0.3	12
118	Treatment algorithm in patients with NSTEMI and unstable angina. , 2012, , 331-346.		0
120	Clinical Use of Clopidogrel. <i>Current Pharmaceutical Design</i> , 2012, 18, 5224-5239.	0.9	28
121	Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5362-5378.	0.9	8
123	Overcoming aspirin treatment failure in diabetes. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 183-198.	2.7	9
124	The case for more intensive use of statins. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 201-210.	1.1	3
125	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 336-346.	1.4	81
126	Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. <i>Vascular Health and Risk Management</i> , 2012, 8, 77.	1.0	35
127	Long-term antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2012, 27, 347-354.	0.8	1
128	Development and Clinical use of Prasugrel and Ticagrelor. <i>Current Pharmaceutical Design</i> , 2012, 18, 5240-5260.	0.9	27
129	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , 2012, 33, 1241-1249.	1.0	127
130	Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 5215-5223.	0.9	12
131	Appropriate Anti-Thrombotic/Anti-Thrombin Therapy for Thrombotic Lesions. <i>Current Cardiology Reviews</i> , 2012, 8, 181-191.	0.6	2
132	Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5273-5293.	0.9	19
133	Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance. <i>Current Pharmaceutical Design</i> , 2012, 18, 5344-5361.	0.9	59
134	Primary and Secondary Prevention of Cardiovascular Disease. <i>Chest</i> , 2012, 141, e637S-e668S.	0.4	435
135	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial. <i>Yearbook of Critical Care Medicine</i> , 2012, 2012, 36-39.	0.2	0
136	Options to Overcome Clopidogrel Response Variability. <i>Circulation Journal</i> , 2012, 76, 287-292.	0.7	27

#	ARTICLE	IF	CITATIONS
137	2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1761-1781.	0.7	256
138	Thienopyridines and Other ADP-Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2012, , 165-198.	0.9	24
139	Personalizing Antiplatelet Therapy With Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 476-85.	2.3	12
140	Bleeding and the Use of Antiplatelet Agents in the Management of Acute Coronary Syndromes and Atrial Fibrillation. <i>Advances in Cardiology</i> , 2012, 47, 125-140.	2.6	0
141	Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. <i>American Heart Journal</i> , 2012, 164, 153-162.e5.	1.2	30
142	Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 393-400.	1.3	37
143	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 173.	0.4	183
144	Residual platelet activity in patients managed with clopidogrel: Clinical implications for the management of patients with acute coronary syndrome. <i>Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.084314 rgt /Overlo</i>	0.8	14
145	Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelorâ€”a long continuing journey. <i>Indian Heart Journal</i> , 2012, 64, 54-59.	0.2	1
148	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 27-42.	0.9	4
150	Prasugrel versus Clopidogrel Antiplatelet Therapy after Acute Coronary Syndrome. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 83-91.	1.0	7
151	Relevancia clÃnica de la interacciÃ³n clopidogrel y omeprazol: revisiÃ³n sistemÃ¡tica. <i>Revista Colombiana De Cardiologia</i> , 2012, 19, 25-32.	0.1	2
152	GuÃa de prÃctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevaciÃ³n persistente del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 173.e1-173.e55.	0.6	31
153	Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke. <i>New England Journal of Medicine</i> , 2012, 367, 817-825.	13.9	586
154	Effect of Addition of Clopidogrel to Aspirin on Mortality. <i>Stroke</i> , 2012, 43, 2157-2162.	1.0	44
155	Aspirin and Other COX-1 Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2012, , 137-164.	0.9	24
156	Unstable Angina and Nonâ€”ST Elevation Myocardial Infarction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 924-932.	2.5	66
157	A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. <i>International Journal of Cardiology</i> , 2012, 160, 109-113.	0.8	15

#	ARTICLE	IF	CITATIONS
158	Quantitative comparison of clopidogrel 600mg, prasugrel and ticagrelor, against clopidogrel 300mg on major adverse cardiovascular events and bleeding in coronary stenting: Synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International Journal of Cardiology, 2012, 158, 181-185.	0.8	19
159	Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 141-151.	1.0	20
160	Newer Pharmaceutical Agents for STEMI Interventions. Interventional Cardiology Clinics, 2012, 1, 429-440.	0.2	0
161	A Risk-Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2012, 91, 829-837.	2.3	24
162	Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. Clinical Pharmacokinetics, 2012, 51, 429-442.	1.6	66
163	The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes. Drugs, 2012, 72, 2087-2116.	4.9	106
164	New Directions in Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2012, 5, 433-445.	1.4	61
165	Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Review of Cardiovascular Therapy, 2012, 10, 489-503.	0.6	11
167	Anti-agrégants plaquettaires et syndromes coronaires aigus : État des lieux et limites actuelles. Archives of Cardiovascular Diseases Supplements, 2012, 4, 232-235.	0.0	0
168	Clinical Application of Cardiovascular Pharmacogenetics. Journal of the American College of Cardiology, 2012, 60, 9-20.	1.2	65
169	2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011) Tj ETQq012 rgBT /Overlock 1		
171	Association Between Periprocedural Bleeding and Long-Term Outcomes Following Percutaneous Coronary Intervention in Older Patients. JACC: Cardiovascular Interventions, 2012, 5, 958-965.	1.1	79
172	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 1231-1238.	1.1	32
173	Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2012, 110, 1200-1206.	0.7	5
174	Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. Primary Care Diabetes, 2012, 6, 167-177.	0.9	10
175	Antiplatelet Agents in Ischemic Heart Disease. Handbook of Experimental Pharmacology, 2012, , 495-518.	0.9	1
176	Ischemic Stroke: Emergencies and Management. Neurologic Clinics, 2012, 30, 187-210.	0.8	5
177	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics, 2012, 1, 223-230.	0.2	3

#	ARTICLE	IF	CITATIONS
179	InforMatrix: ADP antagonists in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 357-385.	0.9	0
181	Effects of Combined Aspirin and Clopidogrel Therapy on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e31642.	1.1	17
182	Reducing co-administration of clopidogrel and proton pump inhibitors in acute coronary syndromes. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2012, 42, 21-23.	0.2	2
183	Aspirin: Pharmacology and Clinical Applications. <i>Thrombosis</i> , 2012, 2012, 1-15.	1.4	48
184	Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin. <i>Thrombosis</i> , 2012, 2012, 1-1.	1.4	3
185	ST Elevation Myocardial Infarction in the elderly. <i>Journal of Geriatric Cardiology</i> , 2012, 9, 108-114.	0.2	8
186	Sangramento em sÃndrome coronariana aguda sem supradesnivelamento de segmento ST. <i>Revista Brasileira De Terapia Intensiva</i> , 2012, 24, 284-293.	0.1	1
187	Acute Coronary Syndrome. , 2012, , 425-434.		0
188	P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 203-205.	1.8	3
189	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.4	318
190	Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. <i>Thrombosis and Haemostasis</i> , 2012, 108, 318-327.	1.8	35
191	A comprehensive comparative review of adenosine diphosphate receptor antagonists. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 175-191.	0.9	11
192	2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Nonâ€“STâ€“Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician. <i>Clinical Cardiology</i> , 2012, 35, 3-8.	0.7	23
193	Aspirin Resistance: Current Status and Role of Tailored Therapy. <i>Clinical Cardiology</i> , 2012, 35, 673-680.	0.7	51
194	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , 2012, 33, 2856-2864.	1.0	64
195	Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus. <i>Herz</i> , 2012, 37, 264-272.	0.4	2
196	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20â€“21, 2011, Salvador, Bahia, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 143-163.	1.0	0
197	Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 20-30.	1.0	2

#	ARTICLE	IF	CITATIONS
198	Which Antiplatelet Agent for Whom? Which Patient Populations Benefit Most from Novel Antiplatelet Agents (Ticagrelor, Prasugrel)?. <i>Current Cardiology Reports</i> , 2012, 14, 486-492.	1.3	7
199	Platelet Function and Inhibition in Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2012, 14, 457-467.	1.3	15
200	Diabetes Mellitus and Acute Coronary Syndrome: Lessons From Randomized Clinical Trials. <i>Current Diabetes Reports</i> , 2012, 12, 294-304.	1.7	33
201	Bridging therapy after recent stent implantation: case report and review of data. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 30-38.	0.3	10
202	Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2012, 37, 237-310.	1.1	14
203	Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. <i>Journal of Internal Medicine</i> , 2012, 271, 521-536.	2.7	18
204	The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 639-646.	1.9	18
205	Justification of 150mg clopidogrel in patients with high on-clopidogrel platelet reactivity. <i>European Journal of Clinical Investigation</i> , 2012, 42, 384-392.	1.7	37
206	Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 181-197.	0.7	7
207	Novel Antiplatelet Therapies. <i>Current Atherosclerosis Reports</i> , 2012, 14, 78-84.	2.0	7
208	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 57-68.	0.4	3
209	Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 24-38.	0.4	10
210	Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 41-51.	1.1	4
212	Estimation of a decreasing hazard of patients with acute coronary syndrome. <i>Statistics in Medicine</i> , 2013, 32, 1223-1238.	0.8	4
213	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 61, 485-510.	1.2	905
214	Medical Management After Coronary Stent Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 189.	3.8	84
215	Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome. <i>BMC Nephrology</i> , 2013, 14, 107.	0.8	15
216	Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5244-5248.	1.0	17

#	ARTICLE	IF	CITATIONS
217	Rationale and Design of the Onâ€Treatment PLATElet Reactivityâ€Guided Therapy Modification FOR STâ€Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. Journal of Interventional Cardiology, 2013, 26, 221-227.	0.5	3
218	Platelet Function Profiles in Patients with Diabetes Mellitus. Journal of Cardiovascular Translational Research, 2013, 6, 329-345.	1.1	46
219	Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments. Cardiology and Therapy, 2013, 2, 47-56.	1.1	7
220	Treatment of NSTEMI (Non-ST Elevation Myocardial Infarction). Current Emergency and Hospital Medicine Reports, 2013, 1, 18-28.	0.6	1
221	Management of STEMI. Current Emergency and Hospital Medicine Reports, 2013, 1, 29-36.	0.6	0
223	Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. Canadian Journal of Cardiology, 2013, 29, 1042-1047.	0.8	19
224	Platelet Function Tests in Clinical Cardiology. Journal of the American College of Cardiology, 2013, 61, 2115-2129.	1.2	74
225	Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology, 2013, 163, 19-25.	0.8	3
226	Prediction of Antiplatelet Effects of Aspirin In Vivo Based on In Vitro Results. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 600-607.	0.7	5
227	Perioperative management of antiplatelet therapy. British Journal of Anaesthesia, 2013, 111, i3-i17.	1.5	81
228	Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. International Journal of Cardiology, 2013, 167, 1794-1797.	0.8	11
229	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 280-291.	0.4	5
230	Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial. International Journal of Cardiology, 2013, 168, 3736-3740.	0.8	102
231	Dual Antiplatelet Therapy Dilemmas: Duration and Choice of Antiplatelets in Acute Coronary Syndromes. Current Cardiology Reports, 2013, 15, 405.	1.3	5
232	Pretreatment with Prasugrel in Nonâ€ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	13.9	539
233	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. Interventional Cardiology, 2013, 5, 179-201.	0.0	0
234	Anticoagulation With Otamixaban and Ischemic Events in Nonâ€ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	3.8	58
235	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	6.3	105

#	ARTICLE	IF	CITATIONS
236	Using Platelet Function Testing to Guide Antiplatelet Therapy. Drug Development Research, 2013, 74, 517-525.	1.4	4
237	Risk of Bleeding on Triple Antithrombotic Therapy After Percutaneous Coronary Intervention/Stenting: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2013, 29, 204-212.	0.8	55
238	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, e78-e140.	1.2	2,612
239	Non-ST-Segment Elevation Acute Coronary Syndromes. , 2013, , 153-177.		0
240	Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology, 2013, 163, 5-18.	0.8	18
241	Individualisation du traitement antiplaquettaire : quel est l'intérêt du monitoring plaquettaire ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2013, 2013, 35-41.	0.0	0
242	Platelet Function and Genetic Testing. Journal of the American College of Cardiology, 2013, 62, S21-S31.	1.2	28
243	Transradial Versus Transfemoral Percutaneous Coronary Intervention in Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2013, 6, 1149-1152.	1.1	45
244	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, e179-e347.	1.2	370
245	STEMI - The importance of balance between antithrombotic treatment and bleeding risk. Cor Et Vasa, 2013, 55, e135-e146.	0.1	1
246	The nuances of new antiplatelet drugs in acute coronary syndrome. Journal of Indian College of Cardiology, 2013, 3, 16-23.	0.1	1
247	Combination Antithrombotic Management for Non-ST Segment Elevation Acute Coronary Syndromes. Interventional Cardiology Clinics, 2013, 2, 553-571.	0.2	0
248	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. International Journal of Cardiology, 2013, 167, 1632-1637.	0.8	7
249	New antiplatelet agents for cardiovascular disease. Cmaj, 2013, 185, 1405-1411.	0.9	10
250	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. Interventional Cardiology Clinics, 2013, 2, 573-583.	0.2	0
253	Antiagregación oral en el intervencionismo coronario percutáneo: fármacos disponibles y duración de la terapia oral. Revista Espanola De Cardiologia Suplementos, 2013, 13, 16-23.	0.2	1
254	Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes. American Journal of Cardiology, 2013, 112, 737-745.	0.7	33
255	How to Manage Antiplatelet Therapy for Stenting in a Patient Requiring Oral Anticoagulants. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 11-20.	0.4	7

#	ARTICLE	IF	CITATIONS
256	Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry. <i>Cardiovascular Intervention and Therapeutics</i> , 2013, 28, 162-169.	1.2	18
257	Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2060-2066.	1.2	225
259	ADP Receptor Antagonists. , 2013, , 1117-1138.		5
260	Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 307-317.	0.6	6
261	Pharmacotherapy for the reduction of stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 567-576.	0.6	1
262	Management of Asymptomatic Carotid Artery Stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 252-263.	0.4	1
263	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. <i>Future Cardiology</i> , 2013, 9, 371-385.	0.5	0
264	Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine. <i>Anatolian Journal of Cardiology</i> , 2013, 13, 486-94.	0.4	2
265	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). , 2013, , 439-457.		0
266	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
267	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2140-2148.	0.8	113
268	Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 233-250.	1.0	36
269	Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. <i>BMJ, The</i> , 2013, 347, f5307.	3.0	52
271	Antiplatelet therapy: new pharmacological agents and changing paradigms. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 316-329.	1.9	61
272	Ticlopidine with Ginkgo Biloba extract: A Feasible Combination for Patients with Acute Cerebral Ischemia. <i>Thrombosis Research</i> , 2013, 131, e147-e153.	0.8	14
273	Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1334-1345.	0.8	97
274	We are 'shocked', 'frozen', and 'freed' by new data. <i>Nature Reviews Cardiology</i> , 2013, 10, 68-70.	6.1	1
275	Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 51-58.	0.9	2

#	ARTICLE	IF	CITATIONS
276	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Nonâ€“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
277	Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 218-228.	0.8	26
278	Do Ingredients Make the Difference?. <i>Circulation</i> , 2013, 127, 566-568.	1.6	2
279	Clopidogrel, Prasugrel, or Ticagrelor? A Practical Guide to Use of Antiplatelet Agents in Patients With Acute Coronary Syndromes. <i>Postgraduate Medicine</i> , 2013, 125, 91-102.	0.9	41
280	ST-Segment Elevation Myocardial Infarction. , 2013, , 178-213.		3
282	Novel Direct-Acting Anticoagulants for Risk Reduction in ACS. <i>Journal of Pharmacy Practice</i> , 2013, 26, 358-366.	0.5	3
283	Evidenced-Based Antithrombotic Therapy for Acute Coronary Syndromes. <i>Diabetes</i> , 2013, 62, 709-710.	0.3	0
284	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. <i>Circulation</i> , 2013, 127, 529-555.	1.6	2,051
285	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e362-425.	1.6	2,639
286	Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 452-459.	1.4	21
287	Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 593-598.	0.5	11
288	Pharmacologic Options for Treatment of Ischemic Disease. , 2013, , 83-130.		4
289	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. <i>Future Cardiology</i> , 2013, 9, 785-797.	0.5	4
290	Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. <i>European Heart Journal</i> , 2013, 34, 894-902.	1.0	21
291	2013 ACCF/AHA Guideline for the Management of STâ€“Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E1-27.	0.7	368
292	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	0.7	45
293	Identifying determinants of variability to tailor aspirin therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 365-379.	0.6	23
294	Approach to patients with aspirin hypersensitivity and acute cardiovascular emergencies. <i>Allergy and Asthma Proceedings</i> , 2013, 34, 138-142.	1.0	28

#	ARTICLE	IF	CITATIONS
295	Clinical importance of antiplatelet drugs in cardiovascular diseases. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 53, 81-96.	0.9	24
296	Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1055-1064.	1.8	10
297	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. <i>Thrombosis and Haemostasis</i> , 2013, 110, 777-784.	1.8	7
298	Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?. <i>Cardiovascular Pharmacology: Open Access</i> , 2013, 2, .	0.1	4
299	The Decline Effect in Cardiovascular Medicine: Is the Effect of Cardiovascular Medicine and Stent on Cardiovascular Events Decline Over the Years?. <i>Korean Circulation Journal</i> , 2013, 43, 443.	0.7	2
300	Efficacy and Safety of Platelet Inhibitors. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 1.	0.9	10
301	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. <i>Thrombosis and Haemostasis</i> , 2013, 109, 834-845.	1.8	28
302	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. <i>Vascular Health and Risk Management</i> , 2014, 10, 177.	1.0	13
303	Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 885.	0.9	1
304	The elusive disconnection between mortality and early stent thrombosis: Observations from the CHAMPION-PHOENIX trial. <i>Thrombosis and Haemostasis</i> , 2014, 111, 8-9.	1.8	0
305	Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2014, 112, 16-25.	1.8	3
306	Optimising pharmacotherapy for secondary prevention of noninvasively managed acute coronary syndrome. <i>Medical Journal of Australia</i> , 2014, 201, S100-5.	0.8	1
307	A Freeze on Tailored Antiplatelet Therapy?. <i>Circulation</i> , 2014, 129, 2088-2090.	1.6	1
308	Cangrelor for treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 565-572.	0.9	4
309	Acute Myocardial Infarction During Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2014, 57, 835-843.	0.6	13
310	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	1.6	24
311	Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014, 35, 209-215.	1.0	224
312	PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1251-1260.	0.6	2

#	ARTICLE	IF	CITATIONS
313	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2563-2571.	1.2	64
314	Pretreatment with P2Y ₁₂ Inhibitors in Non-“ST-Segment” Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36
315	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
316	Outcome Comparison of 600 mg versus 300 mg Loading dose of Clopidogrel for Patients with ST-Elevation Myocardial Infarction: A Meta-Analysis. <i>Postgraduate Medicine</i> , 2014, 126, 177-187.	0.9	7
317	Recent advances in antithrombotic treatment for acute coronary syndromes. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 507-521.	1.3	5
318	Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 63, 339-350.	0.8	64
319	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
320	Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 841.	3.8	44
321	Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: An international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs placebo and clonidine vs placebo in patients undergoing noncardiac surgery. <i>American Heart Journal</i> , 2014, 167, 804-809.e4.	1.2	29
322	Acute Coronary Syndrome. , 2014, , 49-66.		3
323	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 76-89.	0.6	1
324	Aspirin in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1494-1503.	13.9	735
325	Impact of new oral or intravenous P2Y ₁₂ inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2014, 233, 568-578.	0.4	21
326	Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 112-125.	1.1	0
327	Impact of Aspirin Dosing on the Effects of P2Y ₁₂ Inhibition in Patients with Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 19-28.	1.1	17
328	Optimizing P2Y ₁₂ Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1061-1070.	1.2	81
329	Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 63, 225-232.	1.2	30
330	New antiplatelet agents in the treatment of acute coronary syndromes. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 178-187.	0.7	14

#	ARTICLE	IF	CITATIONS
331	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	1.0	171
332	Pharmacotherapeutic Considerations for the Use of Prasugrel and Ticagrelor to Reduce Stent Thrombosis in Patients With Acute Coronary Syndrome. <i>Angiology</i> , 2014, 65, 130-136.	0.8	10
333	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26
334	Optimal aspirin dose in acute coronary syndromes: an emerging consensus. <i>Future Cardiology</i> , 2014, 10, 291-300.	0.5	8
336	Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study. <i>American Heart Journal</i> , 2014, 168, 674-681.e1.	1.2	21
338	Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. <i>European Journal of Pharmacology</i> , 2014, 742, 47-54.	1.7	30
340	Antiplatelet therapy before, during, and after extremity revascularization. <i>Journal of Vascular Surgery</i> , 2014, 60, 1085-1091.	0.6	10
341	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424
342	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. <i>Pharmacotherapy</i> , 2014, 34, 973-990.	1.2	2
343	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
344	Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Heart</i> , 2014, 100, 1750-1756.	1.2	33
347	Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1776-1787.	1.9	61
348	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	0.8	9
349	Do Current Clinical Trials Meet Society's Needs?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1615-1628.	1.2	53
350	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
352	Recent advances in antithrombotic therapy after acute coronary syndrome. <i>Cmaj</i> , 2014, 186, 589-596.	0.9	4
353	Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 302.	0.4	1
354	Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 1146-1152.	0.7	1

#	ARTICLE	IF	CITATIONS
356	Reply. JACC: Cardiovascular Interventions, 2014, 7, 108.	1.1	0
357	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 2014, 114, 1929-1943.	2.0	79
358	Primary Stroke Prevention. Interventional Cardiology Clinics, 2014, 3, 1-11.	0.2	0
360	Antiplatelet Therapy in Patients With Diabetes Mellitus and Acute Coronary Syndrome. Circulation Journal, 2014, 78, 33-41.	0.7	22
361	New Insights for Low Dosing With the New P2Y ₁₂ Inhibitors. Circulation Journal, 2014, 78, 2840-2842.	0.7	2
362	Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surgery, 2015, 15, 112.	0.6	63
364	Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Scientific Reports, 2015, 5, 13789.	1.6	19
365	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
366	Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 2015, 113, 221-230.	1.8	33
367	Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid. Journal of Cardiovascular Pharmacology, 2015, 66, 35-40.	0.8	15
368	Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. Critical Pathways in Cardiology, 2015, 14, 150-153.	0.2	1
369	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. Diabetes and Metabolism Journal, 2015, 39, 95.	1.8	40
370	Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2015, 13, 40-49.	0.4	8
371	Recent advances in the diagnosis and treatment of acute myocardial infarction. World Journal of Cardiology, 2015, 7, 243.	0.5	138
372	Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge. Thrombosis and Haemostasis, 2015, 114, 7-8.	1.8	4
374	SBC Guidelines on Unstable Angina and Non-ST-Elevation Myocardial Infarction: Executive Summary. Arquivos Brasileiros De Cardiologia, 2015, 105, 214-27.	0.3	7
375	P2Y ₁₂ antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Therapeutic Advances in Chronic Disease, 2015, 6, 204-218.	1.1	4
376	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. Circulation, 2015, 132, 174-181.	1.6	45

#	ARTICLE	IF	CITATIONS
377	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2015, 116, 809-817.	0.7	56
378	Design of Major Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2757-2766.	1.2	56
379	Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease. <i>Interventional Cardiology</i> , 2015, 7, 283-293.	0.0	0
380	Challenging Issues in Clinical Trial Design. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2886-2898.	1.2	52
381	Aspirin for primary prevention of cardiovascular disease. <i>Thrombosis Journal</i> , 2015, 13, 38.	0.9	26
383	Managing Acute Coronary Syndromes in the Elderly. <i>The Consultant Pharmacist</i> , 2015, 30, 265-282.	0.4	6
385	New Approaches to Inhibiting Platelets and Coagulation. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 373-397.	4.2	44
386	State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 4.	0.8	16
387	Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002301.	1.4	58
388	Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1983-1995.	0.9	12
389	Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. <i>Drugs</i> , 2015, 75, 1229-1253.	4.9	29
390	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 74-85.	1.2	105
391	Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials. <i>Atherosclerosis</i> , 2015, 240, 439-445.	0.4	28
392	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
393	Multicenter trials, guidelines, and uncertainties – Do we know as much as we think we do?. <i>International Journal of Cardiology</i> , 2015, 187, 600-603.	0.8	8
394	Update on the Guidelines for the Management of ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 3A-9A.	0.7	14
395	Republished: Antiplatelet therapy for secondary prevention of coronary artery disease. <i>Postgraduate Medical Journal</i> , 2015, 91, 284-290.	0.9	1
396	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. <i>Lancet, The</i> , 2015, 386, 281-291.	6.3	209

#	ARTICLE	IF	CITATIONS
397	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. <i>Lancet</i> , The, 2015, 386, 292-302.	6.3	59
398	Exploring PLATO-USA Paradox and CURRENT-OASIS 7 Trials Reveals the Benefit of Higher Aspirin Dose. <i>American Journal of Therapeutics</i> , 2015, 22, 85-86.	0.5	3
399	Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 347-352.	1.9	7
400	Efficacy and safety analysis of new P2Y12inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2015, 31, 2313-2323.	0.9	20
401	Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1739-1747.	0.9	18
403	Platelet progenitors: the hidden drug target. <i>European Heart Journal</i> , 2015, 36, 3211-3213.	1.0	12
404	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2133-2147.	0.9	30
405	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 267-277.	1.6	22
407	Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. <i>Platelets</i> , 2015, 26, 127-131.	1.1	2
408	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47.	6.1	299
409	Why we should not skip aspirin in cardiovascular prevention. <i>Hamostaseologie</i> , 2016, 36, 33-43.	0.9	14
410	When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, 236-46.	0.3	4
411	Type 2 Diabetes and ADP Receptor Blocker Therapy. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	8
413	Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?. <i>Thrombosis and Haemostasis</i> , 2016, 115, 3-6.	1.8	8
414	Management of Patients With NSTEMI-ACS. <i>Journal of the American College of Cardiology</i> , 2016, 68, 313-321.	1.2	62
415	Topical diclofenac does not affect the antiplatelet properties of aspirin as compared to the intermediate effects of oral diclofenac: A prospective, randomized, complete crossover study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 422-428.	1.0	4
416	Aspirin before Coronary Artery Surgery. <i>New England Journal of Medicine</i> , 2016, 375, 90-92.	13.9	7
419	Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 169.	0.7	5

#	ARTICLE	IF	CITATIONS
420	Systematic review and meta-analysis of optimal P2Y ₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. <i>Open Heart</i> , 2016, 3, e000296.	0.9	13
421	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	1.2	69
422	A COGENT Argument for Gastrointestinal Protection With Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1672-1673.	1.2	1
423	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
424	An update on management of the patient presenting with non-ST-elevation acute coronary syndromes. <i>Hospital Practice (1995)</i> , 2016, 44, 173-178.	0.5	1
425	Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. <i>Current Atherosclerosis Reports</i> , 2016, 18, 35.	2.0	12
426	Optimal Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2016, 5, 481-495.	0.2	1
427	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	1.4	10
428	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 609-622.	6.1	24
429	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2016, 18, 81.	1.3	54
430	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet</i> , 2016, 388, 2015-2022.	6.3	303
431	National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. <i>Heart Lung and Circulation</i> , 2016, 25, 895-951.	0.2	222
432	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016, 80, 791-801.	0.7	16
433	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
434	Aspirin Use in Women: Current Perspectives and Future Directions. <i>Current Atherosclerosis Reports</i> , 2016, 18, 74.	2.0	8
435	Parathyroid Hormone Levels and High Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. <i>Cardiovascular Therapeutics</i> , 2016, 34, 209-215.	1.1	9
436	Anti-platelet drugs attenuate the expansion of circulating CD14 ^{high} CD16 ⁺ monocytes under pro-inflammatory conditions. <i>Cardiovascular Research</i> , 2016, 111, 26-33.	1.8	13
437	Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes. <i>Journal of Pharmacy Practice</i> , 2016, 29, 239-249.	0.5	10

#	ARTICLE	IF	CITATIONS
438	Acute Myocardial Infarction in Women. <i>Circulation</i> , 2016, 133, 916-947.	1.6	858
439	Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 11.	2.4	7
440	Percutaneous coronary interventions and antiplatelet therapy in renal transplant recipients. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 86-97.	1.0	3
441	Advanced age and high residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 57-64.	1.9	57
442	Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 2016, , 849-867.e5.		0
444	Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 495-504.	1.6	16
446	Platelets as Biomarkers of Coronary Artery Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 223-233.	1.5	27
447	Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 493-504.	1.0	6
448	Vorapaxar and optimal aspirin dose: The FDA outlook. <i>International Journal of Cardiology</i> , 2016, 203, 903-905.	0.8	2
449	Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines. <i>Journal of the American College of Cardiology</i> , 2016, 67, 216-229.	1.2	23
450	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 321-334.	2.3	3
451	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
452	Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 173-190.	0.4	16
453	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 93-97.	0.4	19
454	The level of free circulating mitochondrial DNA in blood as predictor of death in case of acute coronary syndrome. <i>European Journal of Medical Research</i> , 2017, 22, 1.	0.9	38
455	Validation of Bleeding Classifications in Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2017, 119, 727-733.	0.7	16
456	Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 603-612.	1.2	121
457	Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. <i>American Journal of Emergency Medicine</i> , 2017, 35, 502-507.	0.7	3

#	ARTICLE	IF	CITATIONS
459	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 361-379.	6.1	76
460	Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India. <i>Indian Heart Journal</i> , 2017, 69, S63-S97.	0.2	44
461	Sex differences in cardiovascular disease – Impact on care and outcomes. <i>Frontiers in Neuroendocrinology</i> , 2017, 46, 46-70.	2.5	179
462	Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines for the management of patients with non-ST-segment elevation acute coronary syndromes. <i>Coronary Artery Disease</i> , 2017, 28, 294-300.	0.3	4
463	Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 376, 2053-2064.	13.9	761
464	Thrombosis in diabetes: a shear flow effect?. <i>Clinical Science</i> , 2017, 131, 1245-1260.	1.8	25
465	How I use laboratory monitoring of antiplatelet therapy. <i>Blood</i> , 2017, 130, 713-721.	0.6	42
466	Antiplatelet therapy in acute coronary syndrome. <i>Continuing Cardiology Education</i> , 2017, 3, 11-21.	0.4	1
467	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 123-131.	0.9	6
468	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <i>Open Heart</i> , 2017, 4, e000651.	0.9	49
469	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2048-2090.	1.2	146
470	Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3207-3212.	0.8	1
471	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	71
472	Update on antithrombotic therapy after percutaneous coronary revascularisation. <i>Lancet, The</i> , 2017, 390, 810-820.	6.3	25
473	Optimization of Antiplatelet Therapy in STEMI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 65.	0.4	2
476	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1082.	0.4	189
478	Aspirin and the prevention of venous thromboembolism following total joint arthroplasty. <i>Bone and Joint Journal</i> , 2017, 99-B, 1420-1430.	1.9	80
479	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9

#	ARTICLE	IF	CITATIONS
480	Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent. Archives of Cardiovascular Diseases, 2017, 110, 682-688.	0.7	12
481	Antithrombotic Therapy for ACS in Elderly Patients. Cardiovascular Drugs and Therapy, 2017, 31, 609-618.	1.3	2
482	PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Medical Genetics, 2017, 18, 45.	2.1	13
483	Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. International Journal of Cardiology, 2017, 228, 275-279.	0.8	23
484	Acute myocardial infarction. Lancet, The, 2017, 389, 197-210.	6.3	869
485	Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 133-141.	1.0	2
486	Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. Platelets, 2017, 28, 174-181.	1.1	10
487	Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma. American Journal of Emergency Medicine, 2017, 35, 804.e1-804.e3.	0.7	10
488	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, 13-24.	0.2	6
489	Antithrombotic therapy for acute coronary syndrome: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1240-1248.	1.8	41
490	One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper. Acta Cardiologica, 2017, 72, 19-27.	0.3	3
491	Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI. International Heart Journal, 2017, 58, 167-173.	0.5	3
492	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Current Atherosclerosis Reports, 2018, 20, 15.	2.0	5
493	Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 17.	0.4	1
495	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665.	0.9	15
496	ST-Segment Elevation Myocardial Infarction. , 2018, , 311-327.		4
497	Stable Ischemic Heart Disease. , 2018, , 591-630.		2
498	Selection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. Progress in Cardiovascular Diseases, 2018, 60, 460-470.	1.6	10

#	ARTICLE	IF	CITATIONS
499	Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS. Herz, 2018, 43, 11-19.	0.4	2
500	Clinical implications of genetic variation in carboxylesterase drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 131-142.	1.5	21
501	Coronary Artery Disease in Patients 80 Years of Age. Journal of the American College of Cardiology, 2018, 71, 2015-2040.	1.2	175
502	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
503	Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?. Cor Et Vasa, 2018, 60, e165-e168.	0.1	10
504	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	1.0	7,100
505	Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?. Platelets, 2018, 29, 228-237.	1.1	3
506	Pharmacology of Anticoagulants, Antithrombotics, and Antiplatelet Drugs. , 2018, , 249-258.		0
507	Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction. Medicine (United States), 2018, 97, e13010.	0.4	7
508	Diabetes and antiplatelet therapy: from bench to bedside. Cardiovascular Diagnosis and Therapy, 2018, 8, 594-609.	0.7	45
509	Continuum of Care for Acute Coronary Syndrome. Critical Pathways in Cardiology, 2018, 17, 114-138.	0.2	5
510	OBSOLETE: Unstable Angina: Presentation, Diagnosis, and Management. , 2018, , .		0
511	Implementation of a Nationwide Strategy for the Prevention, Treatment, and Rehabilitation of Cardiovascular Disease - Todo Coraz3n. Archives of Medical Research, 2018, 49, 598-608.	1.5	3
512	Antiplatelet agents in uncertain clinical scenarios - a bleeding nightmare. Cardiovascular Diagnosis and Therapy, 2018, 8, 647-662.	0.7	7
513	Pharmacodynamic Drug - Drug Interactions. , 2018, , 1-10.		0
514	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
515	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
516	Guideline - Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, e009885.	1.6	21

#	ARTICLE	IF	CITATIONS
517	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. Cardiovascular Innovations and Applications, 2018, 3, .	0.1	0
518	Novel Antiplatelet Agents. , 2018, , 391-415.		1
519	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
521	Unstable Angina: Presentation, Diagnosis, and Management. , 2018, , 606-615.		1
522	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. Journal of the Formosan Medical Association, 2018, 117, 766-790.	0.8	44
523	Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2). British Journal of Surgery, 2018, 105, 1591-1597.	0.1	20
524	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. European Heart Journal Supplements, 2018, 20, F1-F74.	0.0	25
525	Antiplatelet and anticoagulation therapy during percutaneous coronary interventions: A review for the interventionalist. Journal of Interventional Cardiology, 2018, 31, 693-704.	0.5	2
526	Non-ST Elevation Myocardial Infarction: Diagnosis and Management. , 0, , .		3
527	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	6.3	155
528	Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. Atherosclerosis, 2019, 289, 118-125.	0.4	6
529	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. American Journal of Medicine, 2019, 132, e569-e580.	0.6	18
530	Analysis of secondary prevention measures implemented in patients with a history of acute coronary syndrome. Revista Colombiana De Cardiologia, 2019, 26, 63-69.	0.1	0
531	Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review. Revista Portuguesa De Cardiologia, 2019, 38, 289-297.	0.2	5
532	Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review. Revista Portuguesa De Cardiologia (English Edition), 2019, 38, 289-297.	0.2	0
533	Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review. Current Cardiology Reports, 2019, 21, 56.	1.3	4
534	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
535	Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 217-224.	1.0	6

#	ARTICLE	IF	CITATIONS
536	The Role of Platelets in Diabetes Mellitus. , 2019, , 469-503.		9
537	P2Y12 Antagonists. , 2019, , 937-956.		1
538	Effectiveness and Safety of Platelet ADPâ€P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2019, 8, e010889.	1.6	5
539	Periprocedural Myocardial Infarction in Contemporary Practice. Interventional Cardiology Clinics, 2019, 8, 209-223.	0.2	6
540	Underutilization of Cardiac Therapies in Patients with Acute Ischemic Stroke and Elevated Troponin. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2019, 17, 144-151.	0.4	2
541	Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. Irish Journal of Medical Science, 2019, 188, 453-467.	0.8	4
542	Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 215-224.	1.0	9
543	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
544	Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis. Journal of the Neurological Sciences, 2019, 397, 174-178.	0.3	9
545	Unstable Angina and Non-ST Elevation Myocardial Infarction. Contemporary Cardiology, 2019, , 233-259.	0.0	0
546	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	6.1	73
547	Colonoscopy in Patients With Postmyocardial Infarction Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2019, 53, 23-28.	1.1	5
548	Modern Management of ST-Segment Elevation Myocardial Infarction. Current Problems in Cardiology, 2020, 45, 100393.	1.1	26
549	Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 14-21.	1.4	4
550	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	1.0	4,210
551	Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. Journal of Arthroplasty, 2020, 35, 886-892.	1.5	44
552	Contemporary NSTEMI management: the role of the hospitalist. Hospital Practice (1995), 2020, 48, 1-11.	0.5	9
554	Pharmacodynamic Drugâ€Drug Interactions. , 2020, , 603-612.		1

#	ARTICLE	IF	CITATIONS
555	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. Journal of Cardiovascular Pharmacology, 2020, 75, 269-275.	0.8	3
556	Rationale and Design of the Aspirin Dosing "A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 2020, 5, 598.	3.0	59
557	Effect of Continued Perioperative Anticoagulant Therapy on Bleeding Outcomes Following Robot-assisted Radical Prostatectomy. Urology, 2021, 148, 151-158.	0.5	4
558	CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105464.	0.7	9
559	Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 109, 1546-1554.	2.3	1
560	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart, 2021, 107, 1739-1747.	1.2	18
561	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis. Frontiers in Pharmacology, 2020, 11, 608247.	1.6	5
562	Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and) Tj ETQq1 1 0,784314,rgBT /Over	0.7	2
563	Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal, 2021, 42, 2235-2259.	1.0	29
564	Antithrombotic strategies in elderly patients with acute coronary syndrome. Archives of Cardiovascular Diseases, 2021, 114, 232-245.	0.7	2
565	Oral Antiplatelet Therapy After Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2021, 325, 1545.	3.8	62
566	A Pharmacogenetic Study of CYP2C19 in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy. Journal of Personalized Medicine, 2021, 11, 400.	1.1	4
567	Reperfusion Strategies in Acute Myocardial Infarction: State of the Art. International Journal of Cardiovascular Sciences, 2021, , .	0.0	0
568	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	13.9	145
569	Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?. European Heart Journal, 2021, 42, 2525-2526.	1.0	1
570	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST " 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	0.3	45
571	Sex-based outcomes in contemporary antiplatelet therapy trials. Open Heart, 2021, 8, e001761.	0.9	4
572	Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 9915.	1.8	7

#	ARTICLE	IF	CITATIONS
573	Non-ST-Elevation Acute Coronary Syndromes. , 2022, , 413-428.		0
574	Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 2022, , 773-785.e4.		0
575	ST-Segment Elevation Myocardial Infarction. , 2022, , 395-411.		1
576	Stable Ischemic Heart Disease Stable Ischemic Heart Disease. , 2015, , 2109-2172.		1
577	Stable Ischemic Heart Disease. , 2014, , 1-70.		1
578	Platelet Inhibitor Agents. , 2012, , 97-112.		2
579	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
580	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circulation Journal, 2019, 83, 1085-1196.	0.7	324
581	Amelioration of Aspirin Induced Oxidative Impairment and Apoptotic Cell Death by a Novel Antioxidant Protein Molecule Isolated from the Herb Phyllanthus niruri. PLoS ONE, 2014, 9, e89026.	1.1	31
582	Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS ONE, 2015, 10, e0134599.	1.1	11
583	Current Antithrombotic Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Interventions. Interventional Cardiology Review, 2011, 9, 94.	0.7	3
584	Comparison of Efficacy between Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome after Interventional Treatment and Their Effects on IL-6. Iranian Journal of Public Health, 0, , .	0.3	1
585	Clopidogrel. American Journal of Cardiovascular Drugs, 2012, 12, 361-374.	1.0	7
586	Antithrombotic Treatment in Diabetes Mellitus: A Review of the Literature about Antiplatelet and Anticoagulation Strategies Used for Diabetic Patients in Primary and Secondary Prevention. Current Pharmaceutical Design, 2020, 26, 2780-2788.	0.9	14
587	Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities. Cardiovascular & Hematological Disorders Drug Targets, 2019, 19, 19-32.	0.2	12
588	Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
589	Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events. Cleveland Clinic Journal of Medicine, 2013, 80, 318-326.	0.6	17
590	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. Materiales De Construccion, 2020, 70, 210.	0.2	15

#	ARTICLE	IF	CITATIONS
591	Acute ST-segment myocardial infarctionâ€”Evolution of treatment strategies. World Journal of Cardiovascular Diseases, 2013, 03, 551-560.	0.0	2
592	Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. EuroIntervention, 2014, 10, 204-211.	1.4	18
593	Contemporary use and outcome of percutaneous coronary interventions in patients with acute coronary syndromes: insights from the 2010 ACSIS and ACSIS-PCI surveys. EuroIntervention, 2012, 8, 465-469.	1.4	19
594	Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention, 2015, 10, 1418-1424.	1.4	23
595	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
597	Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. Nephro-Urology Monthly, 2015, 7, e28099.	0.0	19
599	Silibinin augments the effect of clopidogrel on atherosclerosis in diabetic ApoE deficiency mice. Clinical Hemorheology and Microcirculation, 2022, 80, 353-361.	0.9	4
601	Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 2011, , 971-991.		0
602	Antithrombotic therapy in secondary prevention. Srce I Krvni Sudovi, 2011, 30, 224-233.	0.1	0
603	CURRENT-OASIS: A Potential Mirage of Numbers. Canadian Journal of Hospital Pharmacy, 2011, 64, 155-6.	0.1	0
604	Low-Dose Aspirin Therapy Does not Increase the Severity of Acute Radiation Proctitis. World Journal of Oncology, 2012, 3, 173-181.	0.6	2
605	Pharmacotherapy During Percutaneous Coronary Interventions. , 0, , .		0
610	Agents antiplaquettaires et athÃ©rothrombose. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 375-388.	0.0	0
611	DRUG UTILISATION STUDY IN INTENSIVE CARDIAC CARE UNIT AT A TERTIARY CARE HOSPITAL. Journal of Evolution of Medical and Dental Sciences, 2013, 2, 5239-5250.	0.1	0
612	American Versus European Guidelines: Critical Appraisal. , 2014, , 139-184.		0
613	Percutaneous Coronary Interventions in the Elderly. , 2014, , 243-252.		0
615	Optimizing Intensity and Duration of Oral Antithrombotic Therapy after Primary Percutaneous Coronary Intervention. , 2014, , 569-581.		0
616	Medical Management of Coronary Artery Disease. , 2014, , 1-17.		0

#	ARTICLE	IF	CITATIONS
617	Managing acute coronary syndromes: Decades of progress. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 233-242.	0.6	0
618	Medical Management of Coronary Artery Disease. , 2015, , 2369-2382.		0
620	Stable Ischemic Heart Disease. , 2016, , 1-70.		5
621	Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria. <i>Interni Medicina Pro Praxi</i> , 2016, 18, 184-190.	0.0	0
624	Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Is Less More?. <i>US Cardiology Review</i> , 2018, 12, 91.	0.5	0
625	Treating acute coronary syndrome in the municipal institution for emergency medical aid - Belgrade, Serbia. <i>Naucni Casopis Urgentne Medicine - Halo 194</i> , 2018, 24, 93-101.	0.1	2
626	Review of Antiplatelet Agents. , 2018, , 91-98.		0
627	Management of Coronary Artery Disease & Dyslipidemia and Pharmacist's Role. , 2019, , 169-187.		0
629	(In what extent we reached the standards of antiplatelet therapy in secondary prevention of) Tj ETQq0 0 0 rgBT /Overclock 10 Tf 50 422	0.1	0
630	Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis. <i>Avicenna Journal of Medicine</i> , 2020, 10, 198.	0.3	0
631	Antiplatelet Therapy. <i>Contemporary Cardiology</i> , 2021, , 249-288.	0.0	0
634	Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis. <i>Medical Science Monitor</i> , 2020, 26, e923758.	0.5	3
636	Acute Coronary Syndrome. , 2021, , 59-80.		0
637	Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. <i>American Journal of Cardiovascular Disease</i> , 2011, 1, 255-63.	0.5	1
638	Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION). <i>MĂdică</i> , 2013, 8, 153-63.	0.4	3
639	Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 800-8.	1.3	2
640	Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 11360-9.	1.3	6
641	Comparative Review of Oral P2Y Inhibitors. <i>P and T</i> , 2018, 43, 352-357.	1.0	11

#	ARTICLE	IF	CITATIONS
643	Comparison of Efficacy between Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome after Interventional Treatment and Their Effects on IL-6. Iranian Journal of Public Health, 2020, 49, 240-248.	0.3	1
644	2020 Focused Update of the 2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction. Acta Cardiologica Sinica, 2020, 36, 285-307.	0.1	12
645	Comparative analysis of PIM criteria and drug labels in the elderly. European Journal of Clinical Pharmacology, 2022, 78, 197-204.	0.8	0
646	Regional anaesthesia in patients on antithrombotic drugs. European Journal of Anaesthesiology, 2022, 39, 100-132.	0.7	82
648	Quality care in ST-segment elevation myocardial infarction. Journal of the Chinese Medical Association, 2022, Publish Ahead of Print, .	0.6	1
649	Systemic Immune-Inflammation Index: A Novel Predictor of Coronary Thrombus Burden in Patients with Non-ST Acute Coronary Syndrome. Medicina (Lithuania), 2022, 58, 143.	0.8	9
650	Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment. Lancet Neurology, The, 2022, 21, 355-368.	4.9	89
652	Diagnosis and Treatment of Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2022, 327, 662.	3.8	219
653	The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. Canadian Journal of Cardiology, 2022, 38, S79-S88.	0.8	6
654	Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy. Journal of the Advanced Practitioner in Oncology, 2022, 13, 127-142.	0.2	2
655	Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. International Journal of General Medicine, 2022, Volume 15, 2397-2414.	0.8	3
656	Real-world management and outcomes of 7 million patients with acute coronary syndrome according to clinical research trial enrolment status: a propensity matched analysis. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 409-419.	1.8	3
660	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
661	The association between prothrombin time-international normalized ratio and long-term mortality in patients with coronary artery disease: a large cohort retrospective study with 44,662 patients. BMC Cardiovascular Disorders, 2022, 22, .	0.7	2
662	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. US Cardiology Review, 0, 16, .	0.5	0
663	Low-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum. Cardiology Plus, 2022, 7, 64-69.	0.2	0
664	Fifty years with aspirin and platelets. British Journal of Pharmacology, 2023, 180, 25-43.	2.7	12
665	Antiplatelet Therapy in Coronary Artery Disease: Now and Then. Seminars in Thrombosis and Hemostasis, 0, , .	1.5	2

#	ARTICLE	IF	CITATIONS
666	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. , 2023, 2, 100607.		1
667	Precision antiplatelet therapy. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100138.	1.0	1